AngioDynamics Inc (ANGO) Q1 2026 Earnings Report

AngioDynamics reported QQ1 2026 revenue of $75.71 million, up 6.7% year-over-year, with gross profit of $41.86 million and a gross margin of 55.29%. However, operating income remained negative at -$5.25 million and net income declined to -$10.90 million, translating to an EPS of -$0.26. The quarter delivered revenue momentum but profitability and cash flow remained under pressure due to elevated operating expenses. The company ended the quarter with roughly $38.76 million in cash and equivalents and a net cash position of about -$38.8 million in net debt terms, highlighting a liquidity runway but a need to convert top-line strength into operating income. Looking ahead, management emphasized execution on growth initiatives and portfolio resilience, with a focus on product introductions (e.g., NanoKnife, Solero) and international expansion, while cost control remains a critical lever for margin recovery. Investors should monitor pipeline progression, reimbursement dynamics, and ongoing SG&A discipline as key catalysts for a turnaround.